Journal
CLINICAL IMMUNOLOGY
Volume 134, Issue 1, Pages 66-79Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2009.07.009
Keywords
Atherosclerosis; Immunomodulation; Oxidized LDL; Oxidized phospholipids; Immunization; Tolerance; Antibodies; Adjuvants; Peptide
Categories
Funding
- Austrian Science Fund FWF [W 1205] Funding Source: Medline
Ask authors/readers for more resources
Therapeutic options in atherosclerosis have largely been limited to the control of risk factors, such as hypercholesterotemia, hypertension, or diabetes. However, atherosclerosis is a chronic inflammatory disease in which dyslipidemia and inflammation are equally involved in disease pathogenesis. Moreover, abundant epidemiological and experimental evidence point to an important modulatory role of innate and adaptive immunity in atherogenesis, providing novel therapeutic targets for this disease. Indeed, there is now accumulating data in animal models demonstrating the potential for immunotherapeutic approaches to treat atherosclerosis. These include both general and antigen-specific ways of modulating immune functions, and they show great promise for the development of alternative and/or adjuvant therapies for atherosclerosis. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available